Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug may keep T-Cell lymphoma at bay after transplant

NCT ID NCT07356245

Recruiting now Disease control Sponsor: Jonathan Brammer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing whether the drug ruxolitinib, taken as a daily pill after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD). The study will enroll 44 adults with various T-cell lymphomas who are in remission after their transplant. Ruxolitinib works by calming the immune system and blocking signals that help cancer cells grow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ruxolitinib

What this could lead to

If successful, this could offer a way to reduce the chance of T-cell lymphoma coming back and lower the risk of graft-versus-host disease after a stem cell transplant.

What could go wrong

This is a small, early-phase (phase II) study, so results may not apply to everyone. Ruxolitinib can cause side effects like low blood counts or infections, and it may not prevent relapse or GVHD in all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma graft versus host disease leukemia lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma primary cutaneous T-cell non-Hodgkin lymphoma T-cell non-Hodgkin lymphoma T-cell prolymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT T-CELL LEUKEMIA/LYMPHOMA CUTANEOUS T CELL LYMPHOMA GRAFT VERSUS HOST DISEASE LYMPHOMA, T-CELL PERIPHERAL T CELL LYMPHOMA PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA T CELL LYMPHOMA T-CELL PROLYMPHOCYTIC LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

    Contact